Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

06. Mai 2014 07:30 ET | Quelle: Marina Biotech, Inc.

Marina Biotech Presents Clinical Data Demonstrating Delivery of Both Single and Double-Stranded Nucleic Acids to Tumors

BOSTON, MA--(Marketwired - May 6, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, presented data from...
02. April 2014 09:08 ET | Quelle: Marina Biotech, Inc.

Rosetta Genomics and Marina Biotech Establish Strategic Alliance to Jointly Develop microRNA-Based Diagnostics and Therapeutics for Rare Diseases

PRINCETON, NJ and REHOVOT, ISRAEL and BOSTON, MA--(Marketwired - Apr 2, 2014) - Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and...
11. März 2014 07:30 ET | Quelle: Marina Biotech, Inc.

Marina Biotech to Use Its RNAi, Antisense and microRNA Therapeutics Platform to Develop Drugs for Rare Diseases

BOSTON, MA--(Marketwired - Mar 11, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today...
27. Februar 2014 07:30 ET | Quelle: Marina Biotech, Inc.

Marina Biotech Continues to Build Worldwide Patent Protection for Its SMARTICLES(R) Nucleic Acid Delivery Technology

BOSTON, MA--(Marketwired - Feb 27, 2014) - Marina Biotech, Inc. (OTC Pink: MRNA), a leading oligonucleotide-based drug discovery and development company focused on rare diseases, announced...
24. Februar 2014 07:30 ET | Quelle: Marina Biotech, Inc.

Marina Biotech Announces $6 MM Convertible Preferred Stock Financing and Conversion to Common Stock of the Company's Promissory Note

BOSTON, MA--(Marketwired - Feb 24, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery and development company focused on rare diseases, announced today...
23. Januar 2014 07:30 ET | Quelle: Marina Biotech, Inc.

Marina Biotech Achieves Broad Patent Coverage for DiLA2 Nucleic Acid Delivery Technology in U.S., Europe and Japan

BOSTON, MA--(Marketwired - Jan 23, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery and development company, announced today that a decision to grant a...
14. Januar 2014 07:30 ET | Quelle: Marina Biotech, Inc.

Marina Biotech Strengthens the Intellectual Property Estate for the Transkingdom RNA Interference Nucleic Acid Delivery Technology

BOSTON, MA--(Marketwired - Jan 14, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery and development company, announced today that the Canadian...
09. Januar 2014 07:30 ET | Quelle: Marina Biotech, Inc.

Marina Biotech Strengthens the Intellectual Property Estate for SMARTICLES(R) Nucleic Acid Delivery Technology

BOSTON, MA--(Marketwired - Jan 9, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery and development company, announced today the grant and issuance of...
03. Januar 2014 07:30 ET | Quelle: Marina Biotech, Inc.

Marina Biotech Announces Organizational Changes

BOSTON, MA--(Marketwired - Jan 3, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery and development company, announced today that Philip C. Ranker will...
02. Januar 2014 07:30 ET | Quelle: Marina Biotech, Inc.

Marina Biotech and Mirna Therapeutics Amend License Agreement for the Development of microRNA-Based Therapeutics

BOSTON, MA and AUSTIN, TX--(Marketwired - Jan 2, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery and development company, and Mirna Therapeutics,...

Vorherige Seite

Nächste Seite